Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07451054 · ClinicalTrials.gov registry record · Phase 1
CD45BE-HSPC + CART-45 Cells
A Phase 1 study, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT07451054: Recruiting Phase 1 study, sponsored by University of Pennsylvania.
NCT07451054 is a Phase 1 study that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07451054, a Phase 1 study, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as "CD45BE-HSPC") in patients with relapsed or refractory hematologic malignancies.
Interventions
- BIOLOGICAL CART-45 cells
- BIOLOGICAL CD45BE-HSPC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2026-07 |
| Est. Completion | 2051-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07451054
The ClinicalTrials.gov registry entry for NCT07451054 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CART-45 cells is the first listed.
NCT07451054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07451054 about?
NCT07451054 is a clinical study titled "CD45BE-HSPC + CART-45 Cells". This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cel...
What is the current status of trial NCT07451054?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2026-07. Estimated completion is 2051-07.
What interventions are being tested in trial NCT07451054?
The interventions under investigation include: CART-45 cells (BIOLOGICAL), CD45BE-HSPC (BIOLOGICAL).
Who is sponsoring clinical trial NCT07451054?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.